BGB-3111-206

Completed

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Beigene Study ID info

BGB-3111-206

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20160888

Study Overview

Sex: All

Age: 18 Years / 75 Years

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / 75 Years

Study Documents

Study Protocol Statistical Analysis Plan